A prospective study comparing topical corticosteroids with a combination of topical corticosteroids plus the trial agent (TA) in morphea.

INTERVENTION: Cross body trial of topical betamethasone valerate 0.1% vs topical betamethasone valerate 0.1% and tranilast 1% applied twice daily over a period of 3 months. Monitoring is to be done monthly via LoSCAT scores, laboratory tests and cream return. All other prescribed therapy is to be continued. The dosage of both agents is one finger tip unit (0.5g) per hand sized region (125 sqcm) CONDITION: MORPHEA PRIMARY OUTCOME: The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score SECONDARY OUTCOME: Therapeutic safety is to be monitored via clinical review and laboratory testing INCLUSION CRITERIA: Adults with morphea greater than 18 yrs of age Non pregnant Non lactating No significant renal, hematological or hepatic disease